HeartBeam Announces Commercial Partnership with ClearCardio as First Customer and Strategic Investor

HeartBeam Inc. (NASDAQ: BEAT) announced a commercial partnership with ClearCardio, a preventive cardiology practice serving thousands of patients through heart health screening and personalized prevention programs. ClearCardio will serve as HeartBeam's first commercial customer and plans to make an investment in the company, underscoring strategic alignment between the organizations. The partnership represents a significant milestone for HeartBeam as it transitions from development to commercial deployment of its cardiac monitoring technology.

The staged rollout will integrate HeartBeam's synthesized 12-lead ECG technology into ClearCardio's cardiac prevention program for arrhythmia assessment. This integration will enable patients to capture clinical-grade ECG readings from home using HeartBeam's patented cable-free 3D ECG system. The technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence, allowing physicians to identify cardiac health trends and acute conditions outside of traditional medical facilities. The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025, with details on the intended use available at https://www.heartbeam.com/indications.

Structured as a Letter of Intent outlining subscription-based commercial terms and a collaborative deployment plan, the agreement supports HeartBeam's broader growth strategy. This strategy includes expansion into concierge care and preventive cardiology networks, continued development of its 12-lead ECG patch monitor, and advancement of its AI-driven cardiac care initiatives. The partnership demonstrates the commercial viability of HeartBeam's technology in the growing remote patient monitoring market, particularly within preventive cardiology where early detection of cardiac conditions can significantly impact patient outcomes.

HeartBeam's 3D ECG technology represents a significant advancement in cardiac monitoring, as it creates the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. The company holds over 20 issued patents related to technology enablement, providing intellectual property protection for its innovations. The technology received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for the 12-lead ECG synthesis software in December 2025. This regulatory pathway has positioned the company for commercial partnerships like the one announced with ClearCardio.

The partnership with ClearCardio provides HeartBeam with both immediate commercial revenue through the subscription-based agreement and strategic investment capital to support further development. For ClearCardio, the integration of HeartBeam's technology enhances its preventive cardiology offerings by providing patients with advanced remote monitoring capabilities. This collaboration reflects the growing trend toward decentralized healthcare delivery, where patients can receive clinical-grade monitoring outside traditional healthcare settings. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT, providing investors and stakeholders with ongoing information about the company's progress.